Roche Holding AG raised its guidance on Wednesday after reporting that sales rose 9.5% in the period from January to September.
Sales in the nine months totaled 46.07 billion Swiss francs ($46.16 billion), up from CHF42.08 billion a year earlier. U.S. sales were particularly strong, rising 17% to CHF20.04 billion.
The Swiss drugmaker ROG, +0.88% said it now expects high-single-digit sales growth at constant exchange rates in 2019, with core earnings per share increasing in line with sales.
Previously, the company had guided for mid-to-high-single-digit growth at constant exchange rates.
Roche said a strong performance from multiple sclerosis drug Ocrevus, as well as hemophilia medicine Hemlibra and cancer medicines Tecentriq, Perjeta and Avastin helped to offset declining sales of Herceptin and MabThera/Rituxan, which were hit by competition from closely-resembling drugs.